Compare
Telomir Pharmaceuticals, Inc. vs Ensysce Biosciences, Inc. vs Matinas BioPharma Holdings, Inc. vs Oncolytics Biotech Inc
| Latest fiscal year | Telomir Pharmaceuticals, Inc. TELO | Ensysce Biosciences, Inc. ENSC | Matinas BioPharma Holdings, Inc. MTNB | Oncolytics Biotech Inc ONCY |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $5.07M | n/a | n/a |
| Revenue growth (YoY) | n/a | -2.8% | n/a | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | -202.1% | n/a | n/a |
| Net margin | n/a | -200.8% | n/a | n/a |
| Net income | -$10.41M | -$10.18M | -$10.35M | -$28.76M |
| EPS (Diluted) | -$0.33 | -$3.98 | -$2.00 | -$0.30 |
| Operating cash flow | -$3.69M | -$7.81M | -$7.01M | -$20.11M |
| Free cash flow | n/a | -$7.93M | n/a | -$20.12M |
| Cash & equivalents | n/a | $4.31M | $4.00M | $5.20M |
| Total assets | $7.34M | $7.45M | $7.21M | $7.58M |
| Total liabilities | $1.43M | $4.57M | $2.38M | $11.38M |
| Shareholders' equity | $5.91M | $3.21M | $4.83M | -$3.80M |
| Return on year-end equity | -176.1% | -316.6% | -214.2% | n/a |
| Shares outstanding | 34.38M | 4.57M | 6.41M | 108.02M |
Revenue, most recent five fiscal years
| Fiscal year | Telomir Pharmaceuticals, Inc. | Ensysce Biosciences, Inc. | Matinas BioPharma Holdings, Inc. | Oncolytics Biotech Inc |
|---|---|---|---|---|
| Latest | n/a | $5.07M Ended 2025-12-31 | $1.10M Ended 2023-12-31 | n/a |
| 1 year earlier | n/a | $5.21M Ended 2024-12-31 | $3.19M Ended 2022-12-31 | n/a |
| 2 years earlier | n/a | $2.23M Ended 2023-12-31 | $33.0K Ended 2021-12-31 | n/a |
| 3 years earlier | n/a | $2.52M Ended 2022-12-31 | $158.3K Ended 2020-12-31 | n/a |
| 4 years earlier | n/a | $3.53M Ended 2021-12-31 | $89.8K Ended 2019-12-31 | n/a |